1. AdamsHP Jr, del ZoppoG, AlbertsMJ, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 2007; 38: 1655–711.
2. del ZoppoGJ, SaverJL, JauchEC, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40: 2945–8.
4. LinK, DoKG, OngP, et al. Perfusion CT improves diagnostic accuracy for hyperacute ischemic stroke in the 3-hour window: study of 100 patients with diffusion MRI confirmation. Cerebrovasc Dis 2009; 28: 72–9.
5. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349: 1569–81.
6. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997; 349: 1641–9.
7. BergeE, AbdelnoorM, NakstadPH, SandsetPM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355: 1205–10.
8. HartRG, PalacioS, PearceLA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 2002; 33: 2722–7.
9. HalleviH, AlbrightKC, Martin-SchildS, et al. Anticoagulation after cardioembolic stroke: to bridge or not to bridge? Arch Neurol 2008; 65: 1169–73.
10. AlbersGW, AmarencoP, EastonJD, SaccoRL, TealP. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 suppl): 483S–512S.
11. AdamsHP Jr, BendixenBH, KappelleLJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35–41.
12. U-King-ImJM, TrivediRA, GravesMJ, et al. Contrast-enhanced MR angiography for carotid disease: diagnostic and potential clinical impact. Neurology 2004; 62: 1282–90.
13. BlancoM, NombelaF, CastellanosM, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69: 904–10.
14. PettyGW, BrownRD Jr, WhisnantJP, et al. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998; 50: 208–16.
15. HartmannA, RundekT, MastH, et al. Mortality and causes of death after first ischemic stroke: the Northern Manhattan Stroke Study. Neurology 2001; 57: 2000–5.
16. BravataDM, HoSY, BrassLM, et al. Long-term mortality in cerebrovascular disease. Stroke 2003; 34: 699–704.
17. DeweyHM, SturmJ, DonnanGA, et al. Incidence and outcome of subtypes of ischaemic stroke: initial results from the North East Melbourne stroke incidence study (NEMESIS). Cerebrovasc Dis 2003; 15: 133–9.
18. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–7.
19. HackeW, KasteM, BluhmkiE, et al.; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317–29.
20. MarlerJR, TilleyBC, LuM, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55: 1649–55.
21. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997; 28: 2119–25.
22. PatelSC, LevineSR, TilleyBC, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001; 286: 2830–8.
23. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35: 904–11.
24. SmithWC, SungG, StarkmanS, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005; 36: 1432–8.
25. Penumbra Pivotal Stroke Trial Investigators. The Penumbra Pivotal Stroke Trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009; 40: 2761–8.
26. FurlanA, HigashidaR, WechslerL, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003–11.
27. OgawaA, MoriE, MinematsuK, et al.; MELT Japan Study Group. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007; 38: 2633–9.
28. SmithWS, SungG, SaverJ, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008; 39: 1205–12.
29. KhatriP, HillMD, PaleschYY, et al.; Interventional Management of Stroke III Investigators. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke 2008; 3: 130–7.
30. NoserEA, ShaltoniHM, HallCE, et al. Aggressive mechanical clot disruption: a safe adjunct to thrombolytic therapy in acute stroke? Stroke 2005; 36: 292–6.
31. VoraNA, GuptaR, ThomasAJ, et al. Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke. AJNR Am J Neuroradiol 2007; 28: 1391–4.
32. NogueiraRG, GuptaR, LiebeskindDS, et al. Neither time to treatment nor the use of adjunctive intra-arterial thrombolytics increase the risk for symptomatic intracranial hemorrhage after endovascular treatment of CT perfusion or MRI-selected stroke patients treated at late time windows: analysis of the Pre-DAWN dataset. International Stroke Conference, 2010, San Antonio, TX.
33. TomyczND, HolmMB, HorowitzMB, et al. Extensive brainstem ischemia on neuroimaging does not preclude meaningful recovery from locked-in syndrome: two cases of endovascularly managed basilar thrombosis. J Neuroimaging 2008; 18: 15–17.
34. HillMD, RowleyHA, AdlerF, et al.; PROACT-II Investigators. Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. Stroke 2003; 34: 1925–31.
35. WintermarkM, FlandersAE, VelthuisB, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006; 37: 979–85.
36. SaxenaR, LewisS, BergeE, SandercockPA, Koudstaal, PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001; 32: 2333–7.
37. KangDW, LatourLL, ChalelaJA, DambrosiaJ, WarachS. Early ischemic lesion recurrence within a week after acute ischemic stroke. Ann Neurol 2003; 54: 66–74.
38. LovettJK, CoullAJ, RothwellPM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569–73.
39. VahediK, HofmeijerJ, JuettlerE, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007; 6: 215–22.
40. FiorelliM, BastianelloS, von KummerR, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999; 30: 2280–4.
41. SchneiderLS, DagermanKS, InselP. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–3.
42. SaccoRL, AdamsR, AlbersG, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006; 37: 577–617.
43. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64.
44. YusufS, SleightP, PogueJ, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53.
45. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
46. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
47. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
48. AmarencoP, BogousslavskyJ, CallahanA 3rd, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
49. GrundySM, CleemanJI, MerzCN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–39.
50. TooleJF, MalinowMR, ChamblessLE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565–75.
51. ViscoliCM, BrassLM, KernanWN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243–9.
52. AndersonGL, LimacherM, AssafAR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12.
53. RossouwJE, AndersonGL, PrenticeRL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33.
54. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.
55. DienerHC, CunhaL, ForbesC, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13.
56. The ESPS Group. The European Stroke Prevention Study (ESPS): principal end-points. Lancet 1987; 2: 1351–4.
57. SaccoRL, DienerHC, YusufS, et al.; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238–51.
58. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39.
59. DienerHC, BogousslavskyJ, BrassLM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–7.
60. BhattDL, FoxKA, HackeW, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–17.
61. HartRG, HalperinJL, PearceLA, et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 2003; 138: 831–8.
62. SaxenaR, KoudstaalP. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004; (4): CD000187.
63. FerroJM. Cardioembolic stroke: an update. Lancet Neurol 2003; 2: 177–88.
64. AmarencoP, CohenA, TzourioC, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994; 331: 1474–9.
65. BlackshearJL, ZabalgoitiaM, PennockG, et al. Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. Am J Cardiol 1999; 83: 453–5, A9.
66. MohrJP. Anticoagulation for stroke prevention: yes, no, maybe. Cleve Clin J Med 2004; 71 (Suppl 1): S52–6.
67. HommaS, SaccoRL, Di TullioMR, SciaccaRR, MohrJP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625–31.
68. ChimowitzMI, LynnMJ, Howlett-SmithH, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305–16.
69. MohrJP, ThompsonJL, LazarRM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–51.
70. LevineSR, BreyRL, TilleyBC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576–84.
71. ChobanianAV, BakrisGL, BlackHR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–72.
72. DahlofB, DevereuxRB, KjeldsenSE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
73. PsatyBM, LumleyT, FurbergCD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–4.
74. HolmesDR, ReddyVY, TuriZG, et al.; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534–42.
75. BlockPC, BursteinS, CasalePN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv 2009; 2: 594–600.
76. ConnollySJ, EzekowitzMD, YusufS, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–51.
77. ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360; 2066–78.
78. BarnettHJ. Decision-making for carotid endarterectomy: the trials are only the start. Can J Neurol Sci 2002; 29: 302–4.
79. BarnettHJ, TaylorDW, EliasziwM, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998; 339: 1415–25.
80. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421–8.
81. HallidayA, MansfieldA, MarroJ, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363: 1491–502.
82. YadavJS, WholeyMH, KuntzRE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004; 351: 1493–501.
83. EcksteinHH, RinglebP, AllenbergJR, et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol 2008; 7: 893–902.
84. MasJL, TrinquartL, LeysD, et al. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol 2008; 7: 885–92.
85. BrottTG, HobsonRW 2nd, HowardG, et al.; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363: 11–23.
86. RothwellPM, EliasziwM, GutnikovSA, WarlowCP, BarnettHJ. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363: 915–24.
87. RothwellPM, EliasziwM, GutnikovSA, WarlowCP, BarnettHJ. Sex difference in the effect of time from symptoms to surgery on benefit from carotid endarterectomy for transient ischemic attack and nondisabling stroke. Stroke 2004; 35: 2855–61.
88. BondR, RerkasemK, RothwellPM. Systematic review of the risks of carotid endarterectomy in relation to the clinical indication for and timing of surgery. Stroke 2003; 34: 2290–301.
89. RerkasemK, RothwellPM. Systematic review of the operative risks of carotid endarterectomy for recently symptomatic stenosis in relation to the timing of surgery. Stroke 2009; 40: e564–72.
90. GrubbRL Jr, PowersWJ, DerdeynCP, AdamsHP Jr, ClarkeWR. The carotid occlusion surgery study. Neurosurg Focus 2003; 14 (3): e9.
91. GrubbRL Jr, DerdeynCP, FritschSM, et al. Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA 1998; 280: 1055–60.
92. VernieriF, PasqualettiP, PassarelliF, RossiniPM, SilvestriniM. Outcome of carotid artery occlusion is predicted by cerebrovascular reactivity. Stroke 1999; 30: 593–8.
93. SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004; 35: 1388–92.
94. ZaidatOO, KlucznikR, AlexanderMJ, et al. The NIH registry on the use of the Wingspan stent for symptomatic 70–99% intracranial arterial stenosis. Neurology 2008; 70: 1518–24.
95. YonemuraK, KimuraK, MinematsuK, UchinoM, YamaguchiT. Small centrum ovale infarcts on diffusion-weighted magnetic resonance imaging. Stroke 2002; 33: 1541–4.
96. LandauWM. Clinical neuromythology VI. Au clair de lacune: holy, wholly, holey logic. Neurology 1989; 39: 725–30.
97. PerryHM Jr, DavisBR, PriceTR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000; 284: 465–71.
98. ChenCJ, TsengYC, LeeTH, HsuHL, SeeLC. Multisection CT angiography compared with catheter angiography in diagnosing vertebral artery dissection. AJNR Am J Neuroradiol 2004; 25: 769–74.
99. TouzeE, GauvritJY, MoulinT, et al. Risk of stroke and recurrent dissection after a cervical artery dissection: a multicenter study. Neurology 2003; 61: 1347–51.
100. OverellJR, BoneI, LeesKR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000; 55: 1172–9.
101. MesseSR, SilvermanIE, KizerJR, et al. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004; 62: 1042–50.
102. AlbersGW, CaplanLR, EastonJD, et al. Transient ischemic attack: proposal for a new definition. N Engl J Med 2002; 347: 1713–16.
103. JohnstonSC, GressDR, BrownerWS, SidneyS. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901–6.
104. JohnstonSC, RothwellPM, Nguyen-HuynhMN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007; 369: 283–92.
105. QureshiAI, TuhrimS, BroderickJP, et al. Spontaneous intracerebral hemorrhage. N Engl J Med 2001; 344: 1450–60.
106. MendelowAD, GregsonBA, FernandesHM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365: 387–97.
107. BroderickJP, AdamsHP Jr, BarsanW, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999; 30: 905–15.
108. BrottT, BroderickJ, KothariR, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28: 1–5.
109. WadaR, AvivRI, FoxAJ, SahlasDJ, et al. CT angiography “spot sign” predicts hematoma expansion in acute intracerebral hemorrhage. Stroke 2007; 38: 1257–62.
110. EderiesA, DemchukA, ChiaT, et al. Postcontrast CT extravasation is associated with hematoma expansion in CTA spot negative patients. Stroke 2009; 40: 1672–6.
111. Delgado AlmandozJE, YooAJ, Stone MJ, et al. Systematic characterization of the computed tomography angiography spot sign in primary intracerebral hemorrhage identifies patients at highest risk for hematoma expansion: the spot sign score. Stroke 2009; 40: 2994–3000.
112. MayerSA, BrunNC, BegtrupK, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777–85.
113. MayerSA, BrunNC, BegtrupK, et al.; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127–37.
114. AguilarMI, HartRG, KaseCS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007; 82: 82–92.
115. AndersonCS, HuangY, ArimaH, et al.; INTERACT Investigators. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke 2010; 41: 307–12.
116. LacutK, BressolletteL, Le GalG, et al.; VICTORIAh (Venous Intermittent Compression and Thrombosis Occurrence Related to Intra-cerebral Acute hemorrhage) Investigators. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology 2005; 65: 865–9.
117. BroderickJ, ConnollyS, FeldmannE, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38: 2001–23.
118. BroderickJP, BrottTG, DuldnerJE, TomsickT, HusterG. Volume of intracerebral hemorrhage: a powerful and easy-to-use predictor of 30-day mortality. Stroke 1993; 24: 987–93.
119. HemphillJC, BonovichDC, BesmertisL, ManleyGT, JohnstonSC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001; 32: 891–7.
120. BaileyRD, HartRG, BenaventeO, PearceLA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology 2001; 56: 773–7.
121. HangerHC, WilkinsonTJ, Fayez-IskanderN, SainsburyR. The risk of recurrent stroke after intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2007; 78: 836–40.
122. AzarpazhoohMR, NicolMB, DonnanGA, et al. Patterns of stroke recurrence according to subtype of first stroke event: the North East Melbourne Stroke Incidence Study (NEMESIS). Int J Stroke 2008; 3: 158–64.
123. ZiaE, EngströmG, SvenssonPJ, NorrvingB, Pessah-RasmussenH. Three-year survival and stroke recurrence rates in patients with primary intracerebral hemorrhage. Stroke 2009; 40: 3567–73.
124. GreenbergSM, EngJA, NingM, SmithEE, RosandJ.Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004; 35: 1415–20.
125. MaybergMR, BatjerHH, DaceyR.et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994; 25: 2315–28.
126. MolyneuxA, KerrR, StrattonI, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet 2002; 360: 1267–74.
127. van den BerghWM, AlgraA, van KootenF, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 2005; 36: 1011–15.
128. LongstrethWT Jr, NelsonLM, KoepsellTD, van BelleG. Clinical course of spontaneous subarachnoid hemorrhage: a population-based study in King County, Washington. Neurology 1993; 43: 712–18.
129. KassellNF, TornerJC, JaneJA, HaleyEC Jr, AdamsHP. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 2: surgical results. J Neurosurg 1990; 73: 37–47.
130. International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms: risk of rupture and risks of surgical intervention. N Engl J Med 1998; 339: 1725–33.
131. WiebersDO, WhisnantJP, HustonJ, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003; 362: 103–10.
132. BraininM, OlsenTS, ChamorroA, et al. Organization of stroke care: education, referral, emergency management and imaging, stroke units and rehabilitation. European Stroke Initiative. Cerebrovasc Dis 2004; 17 (Suppl 2): 1–14.
133. HackW, KasteM, BogousslavskyJ, et al. European Stroke Initiative Recommendations for Stroke Management: update 2003. Cerebrovasc Dis 2003; 16: 311–37.
134. SchwammLH, PancioliA, AckerJE, et al. Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association’s Task Force on the Development of Stroke Systems. Stroke 2005; 36: 690–703.
135. Stroke Unit Trialists’ Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Revs 2002; (1): CD000197.
136. AlbertsMJ, HademenosG, LatchawRE, et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA 2000; 283: 3102–9.
137. MeyerBC, RamanR, HemmenT, et al. Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study. Lancet Neurol 2008; 7: 787–95.
138. DuncanPW, ZorowitzR, BatesB, et al.. Management of adult stroke rehabilitation care: a clinical practice guideline. Stroke 2005; 36: e100–43.
139. TepelM, van der GietM, SchwarzfeldC, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180–4.
140. KayJ, ChowWH, ChanTM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003; 289: 553–8.
141. MertenGJ, BurgessWP, GrayLV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328–34.
142. BarberPA, DemchukAM, ZhangJ, BuchanAM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000; 355: 1670–4.
143. EastwoodJD, EngelterST, MacFallJF, DelongDM, ProvenzaleJM. Quantitative assessment of the time course of infarct signal intensity on diffusion-weighted images. AJNR Am J Neuroradiol 2003; 24: 680–7.
144. ParizelPM, MakkatS, Van MiertE, et al. Intracranial hemorrhage: principles of CT and MRI interpretation. Eur Radiol 2001; 11: 1770–83.
145. AlexandrovAV. Cerebrovascular Ultrasound in Stroke Prevention, and Treatment. Elmsford, NY; Oxford: Blackwell/Futura, 2004.
146. AngeliS, Del SetteM, BeelkeM, AnzolaGP, ZanetteE. Transcranial Doppler in the diagnosis of cardiac patent foramen ovale. Neurol Sci 2001; 22: 353–6.
147. JaussM, Zanette, E. Detection of right-to-left shunt with ultrasound contrast agent and transcranial Doppler sonography. Cerebrovasc Dis 2000; 10: 490–6.
148. TothC, VollC. Validation of a weight-based nomogram for the use of intravenous heparin in transient ischemic attack or stroke. Stroke 2002; 33: 670–4.
149. HillbomM, ErilaT, SotaniemiK, et al. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 2002; 106: 84–92.
150. Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. A definition of irreversible coma. JAMA 1968; 205: 337–40.
151. TeasdaleG, JennettB. Assessment of coma and impaired consciousness: a practical scale. Lancet 1974; 2: 81–4.
152. HuntWE, HessRM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968; 28: 14–20.
153. TeasdaleGM, DrakeCG, HuntW, et al. A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies. J Neurol Neurosurg Psychiatry 1988; 51: 1457.
154. RankinJ. Cerebral vascular accidents in patients over the age of 60. Scott Med J 1957; 2: 200–15.
155. BonitaR, BeagleholeR. Modification of Rankin scale: recovery of motor function after stroke. Stroke 1988; 19: 1497–500.
156. Van SwietenJC, KoudstaalPJ, VisserMC, SchoutenHJ, van GijnJ. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604–7.
157. GoldsteinLB, BertelsC, DavisJN. Interrater reliability of the NIH stroke scale. Arch Neurol 1989; 46: 660–2.
158. LydenP, RamanR, LiuL, et al. NIHSS training and certification using a new digital video disk is reliable. Stroke 2005; 36: 2446–9.
